Article
Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution
23 Jan 2023
Abstract excerpt
BACKGROUND: Colorectal cancer liver metastases (CRCLM) are associated with a poor prognosis, reflected by a five-year survival rate of 14%. Anti-angiogenic therapy through anti-VEGF antibody administration is one of the limited therapies available. However, only a subgroup of metastases uses sprouting angiogenesis to secure their nutrients and oxygen supply, while others rely on vessel co-option (VCO). The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
